drugset / Trial / NCT04930432
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, open-label, Phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of MCLA-129.
Timeline
- Start
- 2021-09-24
- Primary completion
- 2028-04-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PAMVATAMIG | Monoclonal antibody | — | Intravenous |